Fluorescein: A Comprehensive Monograph on its Chemistry, Pharmacology, and Evolving Clinical Utility

1.0 Executive Summary

Fluorescein is a synthetic organic xanthene dye that functions as a highly conspicuous fluorophore, a property that has established it as an indispensable diagnostic agent in medicine for over a century. Identified by DrugBank ID DB00693 and CAS Number 2321-07-5, this small molecule is most renowned for its central role in ophthalmology. Administered intravenously as its water-soluble sodium salt, it is the cornerstone of fluorescein angiography, a procedure critical for visualizing the retinal and choroidal vasculature to diagnose and manage a wide spectrum of disorders, including diabetic retinopathy and age-related macular degeneration. In its water-insoluble free acid form, it is applied topically via ophthalmic strips to detect defects in the corneal epithelium, such as abrasions and ulcers. The fundamental mechanism of action is physical rather than pharmacological; it absorbs blue light and emits a brilliant yellowish-green fluorescence, acting as a passive tracer within biological systems. Its pharmacokinetic profile is characterized by rapid distribution, extensive and swift hepatic metabolism to a fluorescent monoglucuronide metabolite, and primary elimination through renal excretion. While generally considered safe, Fluorescein carries a well-defined risk of adverse reactions, ranging from common, mild effects like nausea to rare but life-threatening hypersensitivity events that necessitate universal precautions during intravenous administration. Beyond its traditional ophthalmic applications, Fluorescein is experiencing a renaissance, with its utility expanding into fluorescence-guided surgery for tumor resection, oncology, and forensic science, demonstrating how technological advancements can unlock new potential in a long-established compound.

2.0 Identification and Physicochemical Properties

The precise identification and characterization of Fluorescein's physicochemical properties are fundamental to understanding its formulation, behavior in physiological systems, and ultimate clinical utility.

2.1 Nomenclature and Chemical Identifiers

To ensure unambiguous identification across scientific, clinical, and regulatory domains, Fluorescein is cataloged under numerous systematic names and database identifiers. Its most common name is Fluorescein, though it is also known by synonyms such as Resorcinolphthalein, 3',6'-dihydroxyfluoran, C.I. Solvent Yellow 94, and D&C Yellow No. 7.[1] The primary form, or free acid, is registered under CAS Number 2321-07-5.[2] A comprehensive list of its key identifiers is consolidated in Table 2.1.

Table 2.1: Chemical and Database Identifiers for Fluorescein (CAS 2321-07-5)

Identifier Type	Value	Source(s)
IUPAC Name	3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one	2
DrugBank ID	DB00693	1
CAS Number	2321-07-5	2
PubChem CID	16850	2
ChEBI ID	CHEBI:31624	2
FDA UNII	TPY09G7XIR	2
InChI	InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H	2
InChIKey	GNBHRKFJIUUOQI-UHFFFAOYSA-N	2
SMILES	C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O	2

2.2 Chemical Structure and Molecular Formula

Fluorescein is an organic heteropentacyclic compound with the molecular formula C20​H12​O5​.[2] Its calculated molecular weight is approximately 332.31 g/mol.[3] Structurally, it is classified as a xanthene dye, characterized by a central xanthene ring system. It also contains a gamma-lactone group and two phenol moieties (resorcinol derivatives), classifying it as a polyphenol.[2] The molecule possesses a unique spirocyclic structure, formally an oxaspiro compound, which is integral to its photophysical properties.[2]

2.3 Physical and Chemical Properties

In its solid state, Fluorescein appears as an orange-red to dark red crystalline powder or a yellow amorphous solid.[2] It has a high melting point, reported in the range of 314 °C to 320 °C, often with decomposition.[5]

Its solubility profile is a critical determinant of its formulation and application. Fluorescein free acid is practically insoluble in water, benzene, chloroform, and ether.[2] However, it is soluble in ethanol, methanol, acetone, and, most importantly for its biological activity, in dilute aqueous bases.[2] This alkaline solubility is due to the deprotonation of its phenolic hydroxyl groups. The compound has multiple pKa values, reported as 2.2, 4.4, and 6.7, which govern its ionization state and, consequently, its spectral properties across different pH ranges.[5] Chemically, it is stable under normal conditions but can be sensitive to prolonged light exposure and is incompatible with strong oxidizing agents.[2]

2.4 Spectral Properties

The defining feature of Fluorescein is its intense fluorescence. The molecule absorbs light maximally at a wavelength of approximately 490 nm to 494 nm and emits light with a maximum intensity between 512 nm and 521 nm in aqueous solutions.[1] This large Stokes shift (the difference between excitation and emission maxima) is characteristic of efficient fluorophores. The fluorescence is highly pH-dependent due to its multiple ionization equilibria, with the intense green fluorescence being characteristic of the deprotonated (dianion) form prevalent in alkaline solutions.[10] This property is so potent that the fluorescence is visible even at dilutions of 1:50,000,000.[7]

Visually, this results in a phenomenon known as dichroism: dilute alkaline solutions of Fluorescein appear an intense greenish-yellow by reflected light, while appearing reddish-orange by transmitted light.[2] Fluorescein also exhibits an isosbestic point at 460 nm, a wavelength at which its molar absorptivity is the same for all its ionic forms, making it a useful reference point for pH-independent quantification.[5]

2.5 Related Compounds

A crucial distinction exists between Fluorescein free acid (CAS 2321-07-5) and its disodium salt, Fluorescein Sodium (CAS 518-47-8), also known as uranine.[5] Fluorescein Sodium (

C20​H10​Na2​O5​) is an orange-red powder that is highly soluble in water, forming the basis of all intravenous formulations used in medicine.[12]

This distinction in solubility is not a minor chemical detail but a foundational principle that dictates the drug's clinical use. The specific chemical form is deliberately chosen to match the required route of administration and the physiological environment it will encounter. For systemic applications like angiography, the agent must be fully dissolved in an aqueous vehicle for safe and effective intravenous injection; hence, the highly soluble sodium salt is the only viable option.[12] Conversely, for topical examination of the cornea, the agent is delivered from a solid medium—a paper strip impregnated with the water-insoluble free acid.[14] When the strip is moistened with sterile saline and touched to the eye, a minute amount of the free acid is transferred to the tear film. The tear film's slightly alkaline pH (around 7.4) is sufficient to dissolve and deprotonate the Fluorescein, enabling its characteristic fluorescence and allowing it to pool in and highlight epithelial defects.[1] This elegant form-function relationship, where the fundamental physicochemical properties of two closely related chemical entities are leveraged for distinct clinical purposes, exemplifies a core principle of pharmaceutical formulation.

Other important derivatives include Fluorescein isothiocyanate (FITC), which contains a reactive isothiocyanate group that allows it to be covalently bonded to amine groups on proteins and other biomolecules. This makes FITC an invaluable tool in cellular biology and immunology for fluorescently labeling antibodies and cells for techniques like microscopy and flow cytometry.[5]

3.0 Pharmacology and Mechanism of Action

Fluorescein functions as a diagnostic agent through its physical properties rather than by inducing a pharmacological response. Its mechanism is rooted in the principles of fluorescence, and its utility is derived from its pharmacokinetic behavior as it traces physiological and pathological fluid dynamics.

3.1 Principle of Fluorescence

The mechanism of action of Fluorescein is entirely photophysical. It is a fluorophore, a molecule with a specific conjugated electronic structure that allows it to absorb and re-emit light energy.[16] When exposed to an external light source of an appropriate wavelength, typically cobalt blue light in the range of 465 nm to 490 nm, photons are absorbed by the Fluorescein molecule.[13] This absorption excites electrons within the molecule to a higher, unstable energy state. The electrons remain in this excited state for a very brief period (lifetimes are approximately 3 to 4 nanoseconds) before relaxing back to their stable ground state.[10] As they return to the ground state, the absorbed energy is released in the form of emitted photons. Due to a small, non-radiative loss of energy during the excited state, the emitted photons have a lower energy and thus a longer wavelength than the absorbed photons. This results in the emission of light in the range of 520 nm to 530 nm, which is perceived as a brilliant, characteristic yellowish-green fluorescence.[13] Fluorescein is, therefore, a passive reporter; it does not alter biological processes but simply illuminates them when stimulated by an external light source.

3.2 Pharmacodynamics

As a diagnostic dye, Fluorescein does not possess pharmacodynamic activity in the traditional sense. It does not bind to specific receptors or inhibit enzymes to elicit a therapeutic effect.[1] Its "action" is to serve as a high-contrast tracer, physically distributing within anatomical compartments and highlighting abnormalities in structure or flow.

When administered intravenously for fluorescein angiography, the unbound fraction of the dye circulates within the bloodstream. As it passes through the retinal and choroidal vasculature, it demarcates the blood vessels under observation.[13] In healthy vessels, the tight junctions of the retinal pigment epithelium and retinal capillary endothelium (the blood-retinal barrier) confine the dye within the vascular space. In pathological conditions, such as diabetic retinopathy or neovascular AMD, compromised vessel integrity allows the dye to leak out into the surrounding tissue, producing characteristic patterns of hyperfluorescence that are diagnostic.[18] Conversely, blockages or areas of non-perfusion will appear dark (hypofluorescent).[19]

When applied topically to the ocular surface, the large, lipid-insoluble Fluorescein molecule cannot penetrate the intact, lipophilic corneal epithelium. However, if the epithelium is compromised, the dye penetrates the defect and pools in the underlying hydrophilic stroma. When illuminated with a cobalt blue light, these pooled areas fluoresce brightly, clearly delineating the size, shape, and depth of corneal abrasions, ulcers, or other epithelial disruptions.[15]

3.3 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical utility and safety profile of intravenously administered Fluorescein are governed by its pharmacokinetic properties.

3.3.1 Absorption and Distribution

Following rapid intravenous injection, typically into the antecubital vein, Fluorescein is immediately absorbed into the systemic circulation and distributed throughout the body. Its appearance time in the central retinal artery is remarkably fast, occurring within 7 to 14 seconds of administration.[13] The plasma concentration profile is described by a two-compartment model, with an initial rapid distribution phase followed by a slower elimination phase.[20]

Fluorescein has a volume of distribution of approximately 0.5 L/kg, indicating that it distributes well beyond the plasma volume into the body's interstitial fluid.[13] This widespread distribution is responsible for one of its most common side effects: a temporary, generalized yellowish discoloration of the skin, which typically appears within minutes of injection and fades over 6 to 12 hours as the drug is cleared.[14] In the bloodstream, Fluorescein is moderately and reversibly bound to plasma proteins, primarily albumin, with a binding fraction of approximately 85%.[1] Non-clinical studies in animal models have shown that Fluorescein has a low ability to penetrate the intact blood-brain barrier, a significant safety feature that limits central nervous system exposure.[21]

3.3.2 Metabolism

Fluorescein undergoes rapid and extensive metabolism, primarily through hepatic glucuronidation.[20] The principal metabolite is fluorescein monoglucuronide.[14] This metabolic conversion is remarkably efficient; approximately 80% of the parent drug in the plasma is converted to the glucuronide conjugate within one hour of intravenous administration.[13]

The metabolic fate of Fluorescein introduces a layer of complexity to the interpretation of its diagnostic signal. The fluorescein monoglucuronide metabolite is itself fluorescent, although its molar fluorescent intensity is less than that of the parent compound.[22] Because the conversion is so rapid, a substantial and increasing proportion of the total fluorescence detected in the plasma during the later phases of an angiogram is attributable to this metabolite, not the parent drug. This is a critical pharmacokinetic-pharmacodynamic consideration. The metabolite may possess different physicochemical properties, including its size, charge, and affinity for plasma proteins, which could alter its permeability across compromised vascular barriers compared to the parent drug.[22] Therefore, the patterns of late-stage leakage observed in an angiogram—which are often crucial for diagnosing conditions like cystoid macular edema—are a composite signal from two distinct fluorescent molecules. This nuance is essential for a sophisticated understanding of the procedure, as it suggests that the interpretation of late-phase images may be influenced by the differing pharmacokinetic behaviors of Fluorescein and its primary metabolite.

3.3.3 Excretion

Both the parent Fluorescein molecule and its fluorescein monoglucuronide metabolite are eliminated from the body primarily through renal excretion.[13] The kidneys efficiently filter and secrete both compounds into the urine. This rapid renal clearance leads to another characteristic and benign side effect: the patient's urine becomes a bright, fluorescent yellow color, a phenomenon that persists for 24 to 36 hours post-injection.[13] The systemic clearance of Fluorescein is effectively complete within 48 to 72 hours.[13] Quantitative studies have estimated the renal clearance of Fluorescein to be 1.75 mL/min/kg and the hepatic clearance (attributable to metabolic conjugation) to be 1.50 mL/min/kg, underscoring the importance of both pathways in its disposition.[13] Fluorescein is also known to be excreted into human breast milk.[16]

4.0 Clinical Applications and Efficacy

For decades, Fluorescein has been a cornerstone diagnostic tool, primarily in ophthalmology. However, driven by technological advancements in medical imaging, its applications are expanding into diverse fields, transforming it from a passive dye into an active intraoperative guide.

4.1 Ophthalmic Diagnostic Applications

The utility of Fluorescein in ophthalmology is extensive, encompassing both the posterior and anterior segments of the eye through intravenous and topical administration, respectively.

4.1.1 Intravenous Fluorescein Angiography (IVFA)

IVFA is the principal systemic application of Fluorescein and is indispensable for the diagnosis and management of a wide array of retinal and choroidal diseases.[16] The procedure provides a dynamic map of the ocular vasculature, revealing abnormalities in blood flow and vessel integrity.[19] Key indications include:

• Diabetic Retinopathy: IVFA is crucial for identifying and characterizing macular edema, differentiating between focal leakage from microaneurysms and diffuse leakage from capillaries, which directly guides the application of focal or grid laser photocoagulation.[19] It is also the gold standard for detecting and documenting neovascularization, confirming the progression to the proliferative stage of the disease.[23]
• Age-Related Macular Degeneration (AMD): In the "wet" form of AMD, IVFA is used to identify, localize, and classify choroidal neovascular membranes (CNVMs), which appear as areas of early hyperfluorescence with late leakage. This information is vital for diagnosis and for guiding treatment with anti-VEGF therapies.[19]
• Retinal Vascular Occlusions: The procedure helps to delineate areas of capillary nonperfusion, identify neovascularization, and assess macular edema secondary to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).[19]
• Inflammatory Conditions and Vasculitis: IVFA can confirm the diagnosis of retinal vasculitis by showing leakage from vessel walls and is used to evaluate various inflammatory conditions such as uveitis and posterior scleritis.[10]
• Intraocular Tumors: It aids in the differential diagnosis of intraocular tumors, such as choroidal melanoma and metastasis, based on their characteristic vascular patterns and leakage.[19]
• Other Retinal Disorders: Its applications extend to diagnosing central serous chorioretinopathy (CSCR) by identifying the characteristic "smokestack" or "inkblot" leakage patterns, as well as evaluating macular holes, macular puckers, and ocular ischemic syndrome.[19]

4.1.2 Topical Ophthalmic Examination

The application of topical Fluorescein via sterile paper strips or drops is a routine and essential part of the anterior segment examination.[10] Its primary function is to highlight disruptions in the corneal epithelium. Key uses include:

• Detection of Epithelial Defects: It is used to stain and visualize corneal abrasions, corneal ulcers, and herpetic keratitis (dendritic ulcers).[15] It is also used in the Seidel test to detect full-thickness corneal perforations, where the active leakage of aqueous humor dilutes the dye, creating a visible clear stream within the green tear film.[16]
• Applanation Tonometry: Fluorescein is instilled in the eye to stain the tear film, allowing the mires of the Goldmann applanation tonometer to be clearly visualized for accurate measurement of intraocular pressure.[16]
• Dry Eye Assessment: A standard method for assessing tear film stability is the tear film break-up time (TBUT), which measures the time it takes for dry spots to appear in the fluorescein-stained tear film after a blink.[16]
• Contact Lens Fitting: It is used to evaluate the fit of rigid gas permeable (RGP) contact lenses by revealing the pattern of tear pooling under the lens.[16]
• Other Applications: It is also used to aid in gonioscopy and to identify blockages in the nasolacrimal (tear duct) system.[15]

4.2 Non-Ophthalmic and Investigational Uses

The fundamental principle underlying Fluorescein's utility—its ability to accumulate in and highlight areas of compromised vascular integrity—is now being leveraged in other medical specialties, driven by innovations in imaging technology. This represents a significant paradigm shift, evolving Fluorescein from a passive diagnostic imaging agent into an active, real-time surgical guide. The common mechanistic thread is the extravasation of the dye from "leaky" blood vessels, whether they are in the retina of a diabetic patient or surrounding a malignant brain tumor. The development of surgical microscopes, endoscopes, and probes equipped with the appropriate filters to excite Fluorescein and visualize its emission has unlocked this new potential.

• Fluorescence-Guided Surgery (FGS): Fluorescein is increasingly used intraoperatively to improve the accuracy of surgical resections. In neurosurgery, completed Phase 3 clinical trials have demonstrated its utility in the resection of high-grade gliomas. The dye accumulates in tumor tissue due to the breakdown of the blood-brain barrier, causing the tumor to fluoresce under a specialized surgical microscope and helping the surgeon to better differentiate malignant tissue from healthy brain parenchyma.[10] It is also being investigated in digestive and endocrine surgery using probe-based confocal laser endomicroscopy to assess tissue perfusion and identify anatomical structures.[21]
• Oncology and Cancer Detection: Early-phase clinical trials have explored the use of Fluorescein with intravital microscopy for the real-time evaluation of patients with ovarian, fallopian tube, and primary peritoneal cancers, allowing for microscopic visualization of tumor microvasculature and drug response.[27]
• Forensic Science: Fluorescein has a long-standing application in forensics for the detection of latent blood stains. It reacts with the heme in blood to produce chemiluminescence, revealing traces of blood that are invisible to the naked eye.[2]
• Hydrological Tracing: Due to its high fluorescence quantum yield and low toxicity, it is used as a tracer dye in hydrology to study the flow of groundwater and surface water systems.[7]
• Cellular Biology and Laboratory Research: As previously mentioned, Fluorescein derivatives like FITC are fundamental reagents in life sciences research. They are used to fluorescently label antibodies for immunoassays like ELISA, to tag proteins for tracking within cells, and to label cells for identification and sorting in flow cytometry.[10]

5.0 Dosage, Formulations, and Administration

The safe and effective use of Fluorescein requires a clear understanding of its available formulations, appropriate dosing, and meticulous administration techniques, which differ significantly between its systemic and topical applications.

5.1 Available Formulations

Fluorescein is commercially available in several distinct forms tailored to its specific clinical uses:

• Sterile Solution for Intravenous Injection: This formulation contains the water-soluble disodium salt, Fluorescein Sodium. It is typically supplied in single-use vials or ampules at concentrations of 10% (100 mg/mL) and 25% (250 mg/mL).[1] The solution is a dark reddish-orange color with an alkaline pH between 8.0 and 9.8.[13]
• Sterile Ophthalmic Strips: These are single-use paper strips impregnated with a precise amount of the water-insoluble Fluorescein free acid, commonly 0.6 mg or 1.0 mg per strip. They are used for topical application to the ocular surface.[1]
• Ophthalmic Solutions/Drops: Fluorescein is also available as a topical solution, often in combination products that include a local anesthetic such as benoxinate hydrochloride. This combination allows for simultaneous staining and corneal anesthesia for procedures like tonometry.[16]

5.2 Dosing Regimens

Dosage is determined by the intended application and the patient's age and weight.

• Adults (Intravenous Fluorescein Angiography): The standard adult dose is 500 mg. This is typically administered as 5 mL of the 10% solution or 2 mL of the 25% solution.[13]
• Pediatrics (Intravenous Fluorescein Angiography): The dose for children is calculated based on body weight. The standard calculation is 7.7 mg/kg of actual body weight (equivalent to 35 mg for each ten pounds of body weight), with a maximum dose of 500 mg.[13]

5.3 Method of Administration

Proper administration technique is paramount, particularly for the intravenous route, to ensure efficacy and prevent serious local complications.

• Intravenous Injection: The injection should be administered rapidly (a rate of 1 mL per second is recommended) into a large antecubital vein.[17] Extreme care must be taken to avoid extravasation (leakage of the drug into the surrounding tissue), as the high alkalinity (high pH) of the Fluorescein Sodium solution can cause severe local tissue damage, including pain, inflammation, skin sloughing, and toxic neuritis.[13] A recommended technique to ensure proper venous placement involves using a 23-gauge butterfly needle attached to the syringe. Before injecting the dye, the patient's blood is drawn back into the tubing to the hub of the syringe. The blood is then slowly reinjected while observing the skin over the needle tip. If any bulging of the skin is seen, it indicates extravasation, and the injection must be stopped immediately before any Fluorescein is administered.[13]
• Topical Application: For ophthalmic strips, the sterile strip is first moistened with a drop of sterile saline or water. The patient is asked to look up, and the lower eyelid is gently pulled down. The tip of the moistened strip is then briefly and gently touched to the inferior bulbar or palpebral conjunctiva.[14] The patient is then asked to blink several times to distribute the dye across the ocular surface. It is essential that patients remove contact lenses prior to instillation, as the dye will permanently stain soft contact lenses.[33]

6.0 Safety Profile: Adverse Effects, Contraindications, and Warnings

While Fluorescein is a widely used and generally safe diagnostic agent, it is associated with a range of adverse effects, from common and benign to rare and life-threatening. A thorough understanding of this safety profile is essential for any clinician administering the drug, particularly in its intravenous form.

6.1 Adverse Reactions

Adverse reactions to intravenous Fluorescein can be categorized by their frequency and severity. The majority of reactions are mild and transient, but the potential for severe hypersensitivity events necessitates vigilant patient monitoring.

Table 6.1: Adverse Reactions to Intravenous Fluorescein by Frequency and Severity

System/Category	Common/Very Common (≥1%) / Mild	Uncommon (0.1% to <1%) / Moderate	Rare (<0.1%) / Severe
Gastrointestinal	Nausea, vomiting, abdominal discomfort, strong/metallic taste	Abdominal pain	-
Dermatologic	Yellowish skin discoloration	Urticaria (hives), pruritus (itching), rash	Angioedema
Cardiovascular	Syncope (vasovagal)	Hypotension, thrombophlebitis (at injection site)	Myocardial infarction, cardiac arrest, severe shock, basilar artery ischemia
Respiratory	Sneezing	Cough, throat tightness	Bronchospasm, laryngeal edema, pulmonary edema, respiratory arrest
Neurologic	-	Dizziness, headache, paresthesia	Seizures/convulsions, nerve palsy
Systemic/General	Feeling hot/flushed, extravasation pain	Chills, malaise	Anaphylaxis/anaphylactic shock
Genitourinary	Bright yellow urine discoloration	-	-

• Common Reactions: The most frequently reported adverse effects are gastrointestinal. Nausea, often accompanied by vomiting, occurs in a significant percentage of patients (reports range from 1% to over 10%) within the first few minutes of injection and usually subsides quickly.[14] The transient, benign discoloration of the skin (fading in 6-12 hours) and urine (fading in 24-36 hours) is a universal and expected effect.[13] Vasovagal syncope (fainting) is also relatively common.[31]
• Moderate Reactions: Hypersensitivity reactions manifesting as urticaria and pruritus are the most common moderate events.[31]
• Severe Reactions: Although extremely rare, severe, life-threatening reactions can occur. These include cardiovascular events like myocardial infarction and cardiac arrest, and severe anaphylactic reactions involving bronchospasm, laryngeal edema, and profound hypotension leading to shock.[31] Deaths have been reported but are exceptionally rare.[32]
• Local Reactions: Extravasation of the highly alkaline solution during injection can cause severe local tissue damage, including intense pain, superficial phlebitis, subcutaneous granuloma, and toxic neuritis.[13]

6.2 Contraindications and Precautions

The primary contraindication for Fluorescein is a known history of hypersensitivity to the drug or any of its components.[13] However, managing the risk of adverse reactions requires a broader set of precautions.

A critical point of understanding is that severe adverse reactions to Fluorescein are not always true, IgE-mediated allergic reactions. The underlying pathophysiology can be multifactorial, including direct, non-immune-mediated histamine release (an anaphylactoid reaction) or profound neurally-mediated vasovagal responses.[35] This mechanistic complexity explains why severe reactions can occur in patients with no prior exposure to the drug and why intradermal skin testing, which primarily detects IgE-mediated sensitivity, has very poor predictive value. A negative skin test does not rule out the potential for a life-threatening reaction.[14]

This understanding reframes the clinical approach to safety. While a patient history of allergy (to foods, dyes, or other drugs) or asthma may indicate an increased risk, screening based on allergy history alone is insufficient.[13] The risk of a severe, unpredictable reaction, although very small, is present for every patient receiving an intravenous injection. Therefore, the standard of care must shift from an attempt at risk stratification to a policy of universal precaution. This means that for every administration of intravenous Fluorescein, an emergency tray containing resuscitation equipment, including epinephrine, antihistamines, and corticosteroids, must be immediately accessible, and personnel must be trained in its use.[14]

Regarding specific populations, Fluorescein should be used during pregnancy only if clearly needed, as it is known to cross the placenta.[14] It is also excreted in breast milk, and while no adverse effects in infants have been established, weighing the benefits against potential risks is advised.[20]

6.3 Drug Interactions

While Fluorescein is relatively inert, several clinically significant interactions have been noted:

• Beta-blockers: The concomitant use of beta-blocking agents, including topical ophthalmic formulations (e.g., timolol eye drops), may increase the risk of severe anaphylactic reactions. Furthermore, beta-blockade can blunt the patient's compensatory cardiovascular response to shock and may reduce the effectiveness of epinephrine used to treat the reaction.[31]
• Organic Anion Transporters (OATs): Fluorescein is eliminated via renal OATs. Co-administration of drugs that compete for or inhibit these transporters, such as probenecid, can interfere with Fluorescein's excretion, potentially prolonging its presence in the body and increasing the risk of side effects.[18]
• Laboratory Test Interference: Due to its intense fluorescence, the presence of Fluorescein and its metabolites in blood and urine can interfere with laboratory assays that rely on fluorometric methods. This interference can persist for up to 3 to 4 days following administration, potentially leading to erroneous test results.[31]

7.0 Regulatory and Non-Clinical Information

Fluorescein has a long history of clinical use, which is reflected in its regulatory status and the nature of its non-clinical safety data.

7.1 Regulatory Status and History

Fluorescein sodium for injection is a well-established drug product in the United States and worldwide. It is considered a pre-1938 drug, though its formulation and manufacturing have evolved over time.[42] Key products have been approved by the U.S. Food and Drug Administration (FDA) through New Drug Applications (NDAs), including Funduscein® (NDA 17-869), which was approved on November 10, 1976, and Alcon's Fluorescite® (NDA 21-980), approved on March 28, 2006.[28]

Other manufacturers have gained approval for their versions, such as AK-Fluor® (NDA 22-186), through the 505(b)(2) regulatory pathway. This pathway allows a sponsor to rely, in part, on the FDA's previous findings of safety and efficacy for a listed drug, which is appropriate for a well-characterized agent like Fluorescein.[42] More recently, in September 2023, Nexus Pharmaceuticals received FDA approval for a generic Fluorescein injection, a significant event aimed at addressing industry-wide shortages of the drug that had occurred following the bankruptcy of another manufacturer, Akorn Pharmaceuticals.[44] This underscores the critical and ongoing need for Fluorescein in clinical practice.

7.2 Non-Clinical Toxicology

The non-clinical toxicology profile of Fluorescein is consistent with its intended use as a single-dose or infrequent-use diagnostic agent. Acute toxicity is low, with high median lethal doses (LD50​) in animal models (e.g., ≥ 800 mg/kg intravenously in mice and dogs).[28] Because the drug is not intended for chronic administration, regulatory agencies have not required long-term studies to evaluate its carcinogenic, mutagenic, or reproductive toxicity potential.[13] A 28-day repeated-dose toxicity study in dogs indicated that the toxic intravenous dose was greater than 100 mg/kg, which is many times the standard human dose on a body surface area basis, further supporting its safety for acute diagnostic use.[28]

7.3 Synthesis and Manufacturing

The chemical synthesis of Fluorescein is a classic example of organic chemistry, first described by the Nobel laureate Adolf von Baeyer in 1871.[10] The standard method involves a Friedel-Crafts condensation reaction between one equivalent of phthalic anhydride and two equivalents of resorcinol. The reaction is typically heated, often in the presence of a Lewis acid catalyst like zinc chloride or a protic acid like methanesulfonic acid, to facilitate the reaction and improve yields.[7] This robust and efficient synthesis has allowed for the large-scale production of Fluorescein for over a century; an estimated 250 tons were produced in the year 2000.[10]

8.0 Conclusion

Fluorescein remains a paradigmatic diagnostic agent, whose enduring clinical relevance is a testament to its unique and powerful photophysical properties. For over a century, it has provided clinicians with an unparalleled window into the pathophysiology of the eye, enabling the diagnosis and management of countless vision-threatening diseases. Its pharmacology is straightforward, acting as a passive tracer whose journey through the body illuminates both normal and abnormal biological processes.

However, its apparent simplicity belies a complex safety profile. The risk of rare but severe hypersensitivity reactions—driven by a combination of anaphylactic, anaphylactoid, and vasovagal mechanisms—mandates a clinical approach rooted in universal precaution rather than unreliable risk prediction. Preparedness for an emergency must accompany every intravenous administration.

Looking forward, Fluorescein is not a static relic of medical history. Its fundamental principle—highlighting compromised vasculature—is finding new and powerful applications in fluorescence-guided surgery and oncology, a renaissance driven by parallel advancements in medical imaging technology. This evolution from a passive ophthalmic dye to an active intraoperative tool ensures that Fluorescein, a molecule synthesized in the 19th century, will continue to be a vital component of the diagnostic and therapeutic armamentarium well into the future.

Works cited

1. Fluorescein: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 19, 2025, https://go.drugbank.com/drugs/DB00693
2. Fluorescein | C20H12O5 | CID 16850 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Fluorescein
3. www.scbt.com, accessed August 19, 2025, https://www.scbt.com/p/fluorescein-free-acid-2321-07-5
4. Fluorescein (free acid) - CAS-Number 2321-07-5 - Order from Chemodex, accessed August 19, 2025, https://www.chemodex.com/products/fluorescein-free-acid/
5. Fluorescein | 2321-07-5 - ChemicalBook, accessed August 19, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7753558.htm
6. 3D structure for Fluorescein (DB00693) | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB00693
7. Fluorescein | Fluorescence, Detection, Diagnostics - Britannica, accessed August 19, 2025, https://www.britannica.com/technology/fluorescein
8. CAS Number 2321-07-5 | Fluorescein - Spectrum Chemical, accessed August 19, 2025, https://www.spectrumchemical.com/cas/2321-07-5
9. Fluorescein 2321-07-5 | TCI AMERICA - TCI Chemicals, accessed August 19, 2025, https://www.tcichemicals.com/US/en/p/F0095
10. Fluorescein - Wikipedia, accessed August 19, 2025, https://en.wikipedia.org/wiki/Fluorescein
11. Fluorescein *CAS 2321-07-5* | AAT Bioquest, accessed August 19, 2025, https://www.aatbio.com/products/fluorescein-cas-2321-07-5
12. Sodium Fluorescein | C20H10Na2O5 | CID 10608 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Fluorescein-Sodium
13. Fluorescein Injection: Package Insert / Prescribing Info - Drugs.com, accessed August 19, 2025, https://www.drugs.com/pro/fluorescein-injection.html
14. Fluorescein | Drug Lookup | Pediatric Care Online - AAP Publications, accessed August 19, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5049/Fluorescein
15. Fluorescein eye stain: MedlinePlus Medical Encyclopedia, accessed August 19, 2025, https://medlineplus.gov/ency/article/003845.htm
16. Fluorescein - StatPearls - NCBI Bookshelf, accessed August 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK555957/
17. Fluorescite - Drug Summary - PDR.Net, accessed August 19, 2025, https://www.pdr.net/drug-summary/Fluorescite-fluorescein-1002
18. What is Fluorescein Sodium used for? - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/article/what-is-fluorescein-sodium-used-for
19. Fluorescein Angiography: What It Is and What To Expect - Cleveland Clinic, accessed August 19, 2025, https://my.clevelandclinic.org/health/diagnostics/24618-fluorescein-angiography
20. FluoresciteR (fluorescein injection, USP) 10% - accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021980s000_ClinPharmR.pdf
21. (PDF) Pharmacokinetics and organ distribution of fluorescein in experimental pigs: An input study for confocal laser endomicroscopy of the gastrointestinal tract - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/49711304_Pharmacokinetics_and_organ_distribution_of_fluorescein_in_experimental_pigs_An_input_study_for_confocal_laser_endomicroscopy_of_the_gastrointestinal_tract
22. Fluorescent, physiological and pharmacokinetic properties of fluorescein glucuronide - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/3979458/
23. What Is Fluorescein Angiography? - American Academy of Ophthalmology, accessed August 19, 2025, https://www.aao.org/eye-health/treatments/what-is-fluorescein-angiography
24. Fluorescein Angiography - StatPearls - NCBI Bookshelf, accessed August 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK576378/
25. Fluorescein Completed Phase 3 Trials for Adult Glioblastoma Treatment | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/drugs/DB00693/clinical_trials?conditions=DBCOND0028734&phase=3&purpose=treatment&status=completed
26. All Surgical Conditions Usually Necessitating Frozen Section Completed Phase Trials for Fluorescein (DB00693) | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/indications/DBCOND0078293/clinical_trials/DB00693?phase=&status=completed
27. Fluorescein Completed Phase 0 Trials for Stage III Ovarian Cancer / Stage IIB Ovarian Cancer / Stage IIIB Ovarian Cancer / Primary Peritoneal Carcinoma / Fallopian Tube Carcinoma / Stage IC Ovarian Cancer / Stage IIIC Ovarian Cancer / Ovarian Cancer Stage 1 / Stage IB Ovarian Cancer / Ovarian Cancer Stage 2 / Stage IV Ovarian Cancer / Stage IIIA Ovarian Cancer / Stage IA Ovarian Cancer / Stage IIC Ovarian Cancer / Stage IIA Ovarian Cancer Diagnostic - DrugBank, accessed August 19, 2025, https://go.drugbank.com/drugs/DB00693/clinical_trials?conditions=DBCOND0030366%2CDBCOND0028874%2CDBCOND0044378%2CDBCOND0043203%2CDBCOND0043205%2CDBCOND0043207%2CDBCOND0042654%2CDBCOND0041994%2CDBCOND0041996%2CDBCOND0041998%2CDBCOND0028875%2CDBCOND0030164%2CDBCOND0030165%2CDBCOND0030166%2CDBCOND0030167&phase=0&purpose=diagnostic&status=completed
28. eCopy, Inc. - FDA, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022186s000_PharmR.pdf
29. FLUORESCITE® (fluorescein injection, USP) 10% - accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021980s000lbl.pdf
30. Fluorescein and Benoxinate Ophthalmic Solution: Package Insert / Prescribing Info, accessed August 19, 2025, https://www.drugs.com/pro/fluorescein-and-benoxinate-ophthalmic-solution.html
31. NEW ZEALAND DATA SHEET 1. PRODUCT NAME FLUORESCITETM (fluorescein) Injection 10% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fl - Medsafe, accessed August 19, 2025, https://www.medsafe.govt.nz/profs/datasheet/f/fluoresciteinj.pdf
32. FLUORESCEIN, accessed August 19, 2025, https://pdf.hres.ca/dpd_pm/00057021.PDF
33. Indication-specific dosing for BioGlo, Fluorets, Ful-Glo (fluorescein ophthalmic), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. - Medscape Reference, accessed August 19, 2025, https://reference.medscape.com/drug/bioglo-fluorets-fluorescein-ophthalmic-999591
34. Fluorescein - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed August 19, 2025, https://www.practo.com/medicine-info/fluorescein-2604-api
35. Adverse reactions of fluorescein angiography: a prospective study, accessed August 19, 2025, https://www.aboonline.org.br/export-pdf/1188/v70n4a11.pdf
36. Adverse Reactions Due to Fluorescein during Retinal Angiography - JSciMed Central, accessed August 19, 2025, https://www.jscimedcentral.com/jounal-article-info/JSM-Ophthalmology/Adverse-Reactions-Due-to--Fluorescein-during-Retinal--Angiography-4948
37. Immediate Reactions to Fluorescein and Indocyanine Green in Retinal Angiography: Review of Literature and Proposal for Patient's Evaluation - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6980835/
38. Fluorescein (intravenous route) - Side effects & uses - Mayo Clinic, accessed August 19, 2025, https://www.mayoclinic.org/drugs-supplements/fluorescein-intravenous-route/description/drg-20311323
39. Fluorescein sodium 100 mg/ml, solution for injection - Summary of Product Characteristics (SmPC) - (emc), accessed August 19, 2025, https://www.medicines.org.uk/emc/product/8829/smpc
40. Fluorescein Fundamentals - Ophthalmic Photographers' Society, accessed August 19, 2025, https://www.opsweb.org/?page=FA
41. Fluorescein Sodium 100mg/ml Solution for Injection, accessed August 19, 2025, https://www.medicines.org.uk/emc/files/pil.8829.pdf
42. Statistical Review(s) - accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022186s000_StatR.pdf
43. Drug Approval Package: Fluorescite (fluorescein) NDA #021980, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021980s000TOC.cfm
44. Generic Fluorescite Availability - Drugs.com, accessed August 19, 2025, https://www.drugs.com/availability/generic-fluorescite.html
45. FDA Approves Generic Fluorescein Injection - Knobbe Martens, accessed August 19, 2025, https://www.knobbe.com/blog/fda-approves-generic-fluorescein-injection/